Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
Several ACC 2022 late-breaking trials may have impacts on clinical practice for interventional cardiology and structural heart. One trial compared FFR vs. IVUS guided PCI for intermediate coronary lesions. Photos by Dave Fornell

Key interventional cardiology takeaways from ACC.22

Several late-breaking clinical trials at ACC.22 will likely impact clinical practice. Below are summaries of a few key trials and their takeaways for interventional cardiology and structural heart interventions. 

PCI

Is PCI without stenting safe for low-risk STEMI patients?

The study's authors examined data from the DANAMI-3 trial, focusing on such outcomes as all-cause mortality, recurrent MI and target vessel revascularization.

MitraClip vs mitral valve edge to edge repair (TEER).

VIDEO: MitraClip vs. surgical mitral valve replacement

Joanna Chikwe, MD, founding chair of the department of cardiac surgery at Cedars-Sinai Hospital, compares transcatheter edge-to-edge repair (TEER) to mitral valve surgery for primary mitral regurgitation.

Researchers share first human data on new interventional shunt procedure for HFpEF

The first-in-man study, completed by a team of cardiologists in China, included 10 patients presenting with HFpEF. 

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

Renal denervation linked to significant blood pressure reductions after 3 years

An updated look at patients treated with Medtronic's renal denervation system was presented at ACC.22 and simultaneously published in The Lancet. 

Thumbnail

PCI vs. CABG for left main disease: Key takeaways from a new meta-analysis

Researchers explored data from five different randomized controlled trials, publishing their analysis in the American Journal of Cardiology.

ACC.22 kicked off on Saturday, April 2, in Washington, D.C.

Salt restrictions, PCI breakthroughs and a social media primer for cardiologists: Day 1 at ACC.22

Explore our on-the-ground coverage of the first day of ACC.22.

More than 6,000 IN.PACT Admiral Drug-Coated Balloons have been recalled, Medtronic announced Thursday.

Medtronic recalls more than 6,000 catheters due to potential damage, loss of sterility

The issue, identified during a routine inspection, appears to be related to a change in the manufacturing process. It has now been corrected, Medtronic said in a statement. 

Displaying 617 - 624 of 975
Design by Adaptive Theme